BR112023025436A2 - Piridazinas ou 1,2,4-triazinas substituídas por aminas espirocíclicas - Google Patents
Piridazinas ou 1,2,4-triazinas substituídas por aminas espirocíclicasInfo
- Publication number
- BR112023025436A2 BR112023025436A2 BR112023025436A BR112023025436A BR112023025436A2 BR 112023025436 A2 BR112023025436 A2 BR 112023025436A2 BR 112023025436 A BR112023025436 A BR 112023025436A BR 112023025436 A BR112023025436 A BR 112023025436A BR 112023025436 A2 BR112023025436 A2 BR 112023025436A2
- Authority
- BR
- Brazil
- Prior art keywords
- pyidazines
- triazines
- spirocyclic amines
- replaced
- spirocyclic
- Prior art date
Links
- 150000003920 1,2,4-triazines Chemical class 0.000 title abstract 2
- 150000001412 amines Chemical class 0.000 title abstract 2
- 241000124008 Mammalia Species 0.000 abstract 1
- 101710169972 Menin Proteins 0.000 abstract 1
- 102100030550 Menin Human genes 0.000 abstract 1
- 201000003793 Myelodysplastic syndrome Diseases 0.000 abstract 1
- 201000007224 Myeloproliferative neoplasm Diseases 0.000 abstract 1
- 206010028980 Neoplasm Diseases 0.000 abstract 1
- 201000011510 cancer Diseases 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- 206010012601 diabetes mellitus Diseases 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 239000003112 inhibitor Substances 0.000 abstract 1
- 208000032839 leukemia Diseases 0.000 abstract 1
- 239000008177 pharmaceutical agent Substances 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 238000011321 prophylaxis Methods 0.000 abstract 1
- 230000006916 protein interaction Effects 0.000 abstract 1
- 150000004892 pyridazines Chemical class 0.000 abstract 1
- 238000002560 therapeutic procedure Methods 0.000 abstract 1
- 238000011282 treatment Methods 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/10—Spiro-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Diabetes (AREA)
- General Health & Medical Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Chemical & Material Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Emergency Medicine (AREA)
- Endocrinology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
piridazinas ou 1,2,4-triazinas substi- tuídas por aminas espirocíclicas. a presente invenção refere-se a agentes farmacêuticos úteis para terapia e/ou profilaxia em um mamífero, composição farmacêutica compreendendo tais compostos e usos dos mesmos como inibidores da interação menina/proteína mll/proteína, úteis para o tratamento de do- enças, como câncer, incluindo, mas não se limitando a, leucemia, sín- drome mielodisplásica (smd) e neoplasias mieloproliferativas (nmp), e diabetes.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN2021098067 | 2021-06-03 | ||
| PCT/CN2022/096734 WO2022253289A1 (en) | 2021-06-03 | 2022-06-02 | Pyridazines or 1,2,4-triazines substituted by spirocyclic amines |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BR112023025436A2 true BR112023025436A2 (pt) | 2024-02-27 |
Family
ID=77021000
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BR112023025436A BR112023025436A2 (pt) | 2021-06-03 | 2022-06-02 | Piridazinas ou 1,2,4-triazinas substituídas por aminas espirocíclicas |
Country Status (6)
| Country | Link |
|---|---|
| EP (1) | EP4347600A1 (pt) |
| JP (1) | JP2024521902A (pt) |
| CN (1) | CN117425659A (pt) |
| BR (1) | BR112023025436A2 (pt) |
| CA (1) | CA3218340A1 (pt) |
| WO (1) | WO2022253289A1 (pt) |
Family Cites Families (25)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2011029054A1 (en) | 2009-09-04 | 2011-03-10 | The Regents Of The University Of Michigan | Compositions and methods for treatment of leukemia |
| WO2014164543A1 (en) | 2013-03-13 | 2014-10-09 | The Regents Of The University Of Michigan | Compositions comprising thienopyrimidine and thienopyridine compounds and methods of use thereof |
| WO2016040330A1 (en) | 2014-09-09 | 2016-03-17 | The Regents Of The University Of Michigan | Thienopyrimidine and thienopyridine compounds and methods of use thereof |
| US10588907B2 (en) | 2015-06-04 | 2020-03-17 | Kura Oncology, Inc. | Methods and compositions for inhibiting the interaction of menin with MLL proteins |
| TWI703150B (zh) | 2015-06-04 | 2020-09-01 | 美商庫拉腫瘤技術股份有限公司 | 用於抑制ｍｅｎｉｎ及ｍｌｌ蛋白之交互作用的方法及組合物 |
| KR20180103053A (ko) | 2015-12-22 | 2018-09-18 | 비타이 파마슈티컬즈, 인코포레이티드 | 메닌-mll 상호작용의 억제제 |
| WO2017132398A1 (en) | 2016-01-26 | 2017-08-03 | Memorial Sloan-Kettering Cancer Center | Targeting chromatin regulators inhibits leukemogenic gene expression in npm1 mutant leukemia |
| DK3429591T3 (da) | 2016-03-16 | 2023-06-19 | Kura Oncology Inc | Substituerede thieno[2,3-D]pyrimidin-derivater som inhibitorer af Menin-MLL og fremgangsmåder til anvendelse |
| MX2018011092A (es) | 2016-03-16 | 2018-11-22 | Kura Oncology Inc | Inhibidores biciclicos con puente sustituidos de menina-mll y metodos de uso. |
| CA3022868A1 (en) | 2016-05-02 | 2017-11-09 | Shaomeng Wang | Piperidines as menin inhibitors |
| WO2017207387A1 (en) | 2016-05-31 | 2017-12-07 | Bayer Pharma Aktiengesellschaft | Spiro condensed azetidine derivatives as inhibitors of the menin-mml1 interaction |
| CN109743875B (zh) | 2016-06-10 | 2022-04-29 | 生命医药有限责任公司 | Menin-mll相互作用的抑制剂 |
| WO2018024602A1 (en) | 2016-08-04 | 2018-02-08 | Bayer Aktiengesellschaft | 2,7-diazaspiro[4.4]nonanes |
| WO2018050686A1 (en) | 2016-09-14 | 2018-03-22 | Janssen Pharmaceutica Nv | Spiro bicyclic inhibitors of menin-mll interaction |
| EP3512858B1 (en) | 2016-09-14 | 2023-11-08 | Janssen Pharmaceutica NV | Fused bicyclic inhibitors of menin-mll interaction |
| BR112019005030A2 (pt) | 2016-09-16 | 2019-06-18 | Vitae Pharmaceuticals Inc | inibidores da interação de menina-llm |
| WO2018106820A1 (en) | 2016-12-07 | 2018-06-14 | Kura Oncology, Inc. | Methods of promoting beta cell proliferation |
| WO2018106818A1 (en) | 2016-12-07 | 2018-06-14 | Kura Oncology, Inc. | Methods of promoting beta cell proliferation |
| WO2018109088A1 (en) | 2016-12-15 | 2018-06-21 | Janssen Pharmaceutica Nv | Azepane inhibitors of menin-mll interaction |
| CN108456208B (zh) | 2017-02-22 | 2021-04-16 | 广州市恒诺康医药科技有限公司 | 氮杂螺环类化合物及其制备方法和应用 |
| CN110691779B (zh) | 2017-03-24 | 2023-10-10 | 库拉肿瘤学公司 | 治疗血液系统恶性肿瘤和尤因肉瘤的方法 |
| US11542248B2 (en) | 2017-06-08 | 2023-01-03 | Kura Oncology, Inc. | Methods and compositions for inhibiting the interaction of menin with MLL proteins |
| TW201920170A (zh) | 2017-09-20 | 2019-06-01 | 美商庫拉腫瘤技術股份有限公司 | 經取代之menin-mll 抑制劑及使用方法 |
| WO2020069027A1 (en) | 2018-09-26 | 2020-04-02 | Kura Oncology, Inc. | Treatment of hematological malignancies with inhibitors of menin |
| EP4077312A4 (en) | 2019-12-19 | 2024-01-17 | Janssen Pharmaceutica NV | SUBSTITUTED STRAIGHT CHAIN SPIRO DERIVATIVES |
-
2022
- 2022-06-02 EP EP22729426.1A patent/EP4347600A1/en active Pending
- 2022-06-02 JP JP2023574388A patent/JP2024521902A/ja active Pending
- 2022-06-02 CA CA3218340A patent/CA3218340A1/en active Pending
- 2022-06-02 BR BR112023025436A patent/BR112023025436A2/pt unknown
- 2022-06-02 CN CN202280039198.7A patent/CN117425659A/zh active Pending
- 2022-06-02 WO PCT/CN2022/096734 patent/WO2022253289A1/en active Application Filing
Also Published As
| Publication number | Publication date |
|---|---|
| WO2022253289A1 (en) | 2022-12-08 |
| JP2024521902A (ja) | 2024-06-04 |
| CA3218340A1 (en) | 2022-12-08 |
| EP4347600A1 (en) | 2024-04-10 |
| CN117425659A (zh) | 2024-01-19 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BR112019004764A2 (pt) | inibidores bicíclicos fundidos da interação menina-mll | |
| CR20220346A (es) | Derivados espiráncos sustituidos de cadena lineal | |
| EA201990699A1 (ru) | Спиробициклические ингибиторы взаимодействия менин–mll | |
| BR112019004691A2 (pt) | inibidores bicíclicos em espiro da interação menina-mll | |
| ECSP19083621A (es) | Derivados de indolina sustituidos como inhibidores de la replicación vírica de dengue | |
| ECSP19070369A (es) | Derivados de indolina sustituidos como inhibidores de la replicación vírica de dengue | |
| ECSP18073293A (es) | Derivados de indolina sustituidos como inhibidores de la replicación viral del dengue | |
| ECSP19070413A (es) | Derivados de indolina sustituidos como inhibidores de la replicación vírica de dengue | |
| ECSP18073366A (es) | Derivados de indolina sustituidos como inhibidores de la replicación vírica de dengue | |
| ECSP19083640A (es) | Derivados de indolina sustituidos como inhibidores de la replicación vírica de dengue | |
| BR112015027380A2 (pt) | Composições antimicrobianas e métodos para a sua produção | |
| BR112017007708A2 (pt) | composto macrocíclicos, uso de um composto macrocíclicos, método para tratamento, unidade de dose, composição farmacêutica e método para tratar câncer em um paciente | |
| MX2020006594A (es) | Inhibidores de exo-azaespiro de la interaccion menina-mll. | |
| BR112022000251A2 (pt) | Derivados macrocíclicos de espirociclo como inibidores de mcl-1 | |
| MX2023014347A (es) | Derivados de fenil-1h-pirrolo[2,3-c]piridina sustituidos. | |
| BR112023000212A2 (pt) | Éter macrocíclico contendo derivados de indol como inibidores de mcl-1 | |
| CO2023005057A2 (es) | Compuestos y composiciones como moduladores de señalización tlr | |
| CO2021013171A2 (es) | Compuestos y composiciones como moduladores de la señalización de tlr | |
| BR112023025436A2 (pt) | Piridazinas ou 1,2,4-triazinas substituídas por aminas espirocíclicas | |
| BR112023021040A2 (pt) | Derivados espiro substituídos | |
| BR112023023154A2 (pt) | Derivados espiro substituídos | |
| BR112019012106A2 (pt) | inibidores de azepano de interação menin-mill | |
| CO2023018577A2 (es) | Sal de besilato de (r)-n-etil-5-fluoro-n-isopropil-2-((5-(2-(6-((2-metoxietil)(metil)amino)-2-metilhexan-3-il)-2,6-diazaspiro[3.4]octan-6-il)-1,2,4-triazin-6-il)oxi)benzamida para el tratamiento de enfermedades tales como el cáncer | |
| BR112022016444A2 (pt) | Derivados de indol macrocíclico como inibidores de mcl-1 | |
| BR112017012355A2 (pt) | composição farmacêutica compreendendo composto amida heterocíclica aromática contendo nitrogênio bicíclico como ingrediente ativo |